Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 6
2003 10
2004 10
2005 11
2006 11
2007 10
2008 16
2009 18
2010 18
2011 12
2012 13
2013 7
2014 17
2015 9
2016 16
2017 17
2018 19
2019 13
2020 28
2021 33
2022 25
2023 20
2024 15

Text availability

Article attribute

Article type

Publication date

Search Results

308 results

Results by year

Filters applied: . Clear all
Page 1
Enhanced recovery after surgery (ERAS) in gynecology oncology.
Bogani G, Sarpietro G, Ferrandina G, Gallotta V, DI Donato V, Ditto A, Pinelli C, Casarin J, Ghezzi F, Scambia G, Raspagliesi F. Bogani G, et al. Among authors: ferrandina g. Eur J Surg Oncol. 2021 May;47(5):952-959. doi: 10.1016/j.ejso.2020.10.030. Epub 2020 Oct 28. Eur J Surg Oncol. 2021. PMID: 33139130 Review.
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, Bologna A, Weber B, Raspagliesi F, Panici PB, Cormio G, Sorio R, Cavazzini MG, Ferrandina G, Breda E, Murgia V, Sacco C, Cinieri S, Salutari V, Ricci C, Pisano C, Greggi S, Lauria R, Lorusso D, Marchetti C, Selvaggi L, Signoriello S, Piccirillo MC, Di Maio M, Perrone F; Multicentre Italian Trials in Ovarian cancer (MITO-7); Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens et du sein (GINECO); Mario Negri Gynecologic Oncology (MaNGO); European Network of Gynaecological Oncological Trial Groups (ENGOT-OV-10); Gynecologic Cancer InterGroup (GCIG) Investigators. Pignata S, et al. Among authors: ferrandina g. Lancet Oncol. 2014 Apr;15(4):396-405. doi: 10.1016/S1470-2045(14)70049-X. Epub 2014 Feb 28. Lancet Oncol. 2014. PMID: 24582486 Clinical Trial.
Radiomics systematic review in cervical cancer: gynecological oncologists' perspective.
Bizzarri N, Russo L, Dolciami M, Zormpas-Petridis K, Boldrini L, Querleu D, Ferrandina G, Pedone Anchora L, Gui B, Sala E, Scambia G. Bizzarri N, et al. Among authors: ferrandina g. Int J Gynecol Cancer. 2023 Oct 2;33(10):1522-1541. doi: 10.1136/ijgc-2023-004589. Int J Gynecol Cancer. 2023. PMID: 37714669 Review.
New medical approaches in advanced ovarian cancer.
Corrado G, Palluzzi E, Bottoni C, Pietragalla A, Salutari V, Ghizzoni V, Distefano M, Scambia G, Ferrandina G. Corrado G, et al. Among authors: ferrandina g. Minerva Med. 2019 Aug;110(4):367-384. doi: 10.23736/S0026-4806.19.06139-1. Epub 2019 May 22. Minerva Med. 2019. PMID: 31124637 Review.
Optimizing treatment in recurrent epithelial ovarian cancer.
Corrado G, Salutari V, Palluzzi E, Distefano MG, Scambia G, Ferrandina G. Corrado G, et al. Among authors: ferrandina g. Expert Rev Anticancer Ther. 2017 Dec;17(12):1147-1158. doi: 10.1080/14737140.2017.1398088. Epub 2017 Nov 6. Expert Rev Anticancer Ther. 2017. PMID: 29086618 Review.
Novel targets for VEGF-independent anti-angiogenic drugs.
Petrillo M, Scambia G, Ferrandina G. Petrillo M, et al. Among authors: ferrandina g. Expert Opin Investig Drugs. 2012 Apr;21(4):451-72. doi: 10.1517/13543784.2012.661715. Epub 2012 Feb 20. Expert Opin Investig Drugs. 2012. PMID: 22339615 Review.
Assessing the role of minimally invasive radical hysterectomy for early-stage cervical cancer.
Bogani G, Di Donato V, Muzii L, Casarin J, Ghezzi F, Malzoni M, Greggi S, Landoni F, Bazzurini L, Zanagnolo V, Multinu F, Angioli R, Plotti F, Caruso G, Fischetti M, Ferrandina G, Palaia I, Benedetti Panici P, Scambia G, Raspagliesi F. Bogani G, et al. Among authors: ferrandina g. Eur J Obstet Gynecol Reprod Biol. 2022 Aug;275:64-69. doi: 10.1016/j.ejogrb.2022.06.004. Epub 2022 Jun 8. Eur J Obstet Gynecol Reprod Biol. 2022. PMID: 35753229 Review.
Targeting CD133 antigen in cancer.
Ferrandina G, Petrillo M, Bonanno G, Scambia G. Ferrandina G, et al. Expert Opin Ther Targets. 2009 Jul;13(7):823-37. doi: 10.1517/14728220903005616. Expert Opin Ther Targets. 2009. PMID: 19530986 Review.
Investigational agents against platinum-resistant ovarian cancer.
Lorusso D, Ferrandina G, Fanfani F, Gagliardi ML, Scambia G. Lorusso D, et al. Among authors: ferrandina g. Expert Opin Investig Drugs. 2007 Mar;16(3):325-36. doi: 10.1517/13543784.16.3.325. Expert Opin Investig Drugs. 2007. PMID: 17302527 Review.
308 results